Undisclosed

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Lonza Partners with Anthos Therapeutics for Thrombosis Treatment

Lead Product(s): Abelacimab

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Anthos Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 11, 2020

Details:

The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

VarmX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VarmX Raises €32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on Oral Anticoagulants

Lead Product(s): VMX-COO1

Therapeutic Area: Hematology Product Name: VMX-COO1

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Ysios Capital

Deal Size: $36.6 million Upfront Cash: Undisclosed

Deal Type: Series B Financing July 08, 2020

Details:

Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.

Shanghai Cell Therapy Group

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Shanghai Cell Therapy Group Ink Collaboration with USC to Improve Ex Vivo Expansion of Hematopoietic Stem Cells for Clinical Applications

Lead Product(s): Hematopoietic stem cells

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Baize Plan Fund

Deal Size: $3.6 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 28, 2020

Details:

Through the project, sponsored by the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.